Table 6.

Mediation analysis of the role between telomere length, lipids and ALS/FTD.

Pop	Exposure	Mediator	Outcome	ab (Sab)	95% CI	Z	p
EUR	LTL	HDL	ALS	0.001 (0.003)	− 0.005–0.007	0.354	0.724
	LTL	LDL	ALS	0.007 (0.004)	− 0.001–0.014	1.754	0.079
	LTL	TC	ALS	0.006 (0.003)	− 0.001–0.013	1.682	0.092
	LTL	TG	ALS	0.004 (0.004)	− 0.004–0.012	1.021	0.307
	LTL	HDL	FTD	− 0.003 (0.010)	− 0.022–0.016	− 0.298	0.766
	LTL	LDL	FTD	0.008 (0.007)	− 0.005–0.022	1.194	0.232
	LTL	TC	FTD	0.008 (0.007)	− 0.005–0.022	1.227	0.220
	LTL	TG	FTD	0.002 (0.013)	− 0.023–0.027	0.134	0.893
Asian	LTL	HDL	ALS	− 0.002 (0.002)	− 0.006–0.002	− 1.048	0.295
	LTL	LDL	ALS	− 0.001 (0.004)	− 0.009–0.008	− 0.157	0.875
	LTL	TC	ALS	0.001 (0.002)	− 0.004–0.005	0.223	0.824
	LTL	TG	ALS	0.003 (0.003)	− 0.003–0.009	0.916	0.360

Pop population, EUR European, LTL leukocyte telomere length, HDL high density lipoprotein, LDL low density lipoprotein, TC total cholesterol, TG triglycerides, ALS amyotrophic lateral sclerosis, FTD frontotemporal dementia, ab the mediation effect, S_ab standard error of the mediation effect, CI, Z and p represent confidence internal, Z statistic and p value, respectively.

The marginally significant mediated effect of LTL on the risk of ALS by LDL or TC are shown in bold.